etonogestrel (3-oxodesogestrel)
Jump to navigation
Jump to search
Indications
- progestin used in progestin-only implant* (Implanon) & in combination with ethinyl estradiol in NuvaRing
* subdermal etonogestrel-releasing implants are the most effective contraceptives available[2]
Dosage
Pharmacokinetics
- metabolized by cyt P450 3A4
- active metabolite of desogestrel
Adverse effects
- unscheduled uterine bleeding
- ulipristal acetate 15 mg PO QD for 7 days of benefit[3]
More general terms
Component of
- estradiol/etonogestrel
- ethinyl estradiol/etonogestrel
- NuvaRing (etonogestrel, ethinyl estradiol)
- etonogestrel implant (Implanon)
References
- ↑ Prescriber's Letter 9(6):32 2002
- ↑ 2.0 2.1 2.2 Bimla Schwarz E The Etonogestrel-Releasing Contraceptive Implant: Why Stop at 3 Years? NEJM Journal Watch. Oct 20, 2016 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
Ali M, Akin A, Bahamondes L et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: Comparison to levonorgestrel- releasing subdermal implant. Hum Reprod 2016 Sep 26 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27671673 Free Article - ↑ 3.0 3.1 Zigler RE, Madden T, Ashby C, Wan L, McNicholas C. Ulipristal acetate for unscheduled bleeding in etonogestrel implant users: A randomized controlled trial. Obstet Gynecol. 2018 Oct;132(4):888-894. ePub Aug 17, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30130351